Ear­li­er this month, a new can­cer drug cap­ti­vat­ed pa­tients and in­vestors.

Now the lawyers get their turn.

On Mon­day, the biotech Eras­ca said it had re­ceived a le­gal threat from Rev­o­lu­tion Med­i­ci­nes' lawyers over its can­cer drug ERAS-0015, which is be­ing test­ed in sol­id tu­mors — and which will re­port out high­ly an­tic­i­pat­ed da­ta lat­er on Mon­day. Rev­o­lu­tion's drug darax­on­ra­sib has shown ex­cit­ing re­sults in hard-to-treat pan­cre­at­ic can­cer. Both drugs tar­get RAS, a path­way in­volved in can­cer that has been no­to­ri­ous­ly dif­fi­cult to at­tack.

Ac­cord­ing to a se­cu­ri­ties fil­ing from Eras­ca on Mon­day, Rev­o­lu­tion is al­leg­ing that Eras­ca's drug is "sub­stan­tial­ly equiv­a­lent" to Rev­o­lu­tion's drug, in­fring­ing on its patents, and that its trade se­crets have been vi­o­lat­ed. Lawyers for Rev­o­lu­tion al­so took is­sue with how Eras­ca has com­pared pre­clin­i­cal da­ta for ERAS-0015 to darax­on­ra­sib, ac­cord­ing to the fil­ing.

In­di­an drug gi­ant Sun Phar­ma has lined up an $11.75 bil­lion ac­qui­si­tion of Organon, a women’s health and biosim­i­lar mak­er spun out of Mer­ck in 2021.

The all-cash deal came in at $14 per share OGN and is slat­ed to close ear­ly next year, the com­pa­nies said Sun­day evening.

At near­ly $12 bil­lion, it marks the largest phar­ma M&A deal of 2026 so far and one of the biggest drug­mak­er trans­ac­tions in re­cent years. The merg­er adds to the blis­ter­ing pace of bio­phar­ma M&A over the past two quar­ters as drug­mak­ers fill their pipelines.

Sun Phar­ma gains ac­cess to a suite of brand­ed prod­ucts, gener­ics and biosim­i­lars. The move po­si­tions it as one of the top three com­pa­nies in glob­al women’s health, Sun Phar­ma said. It will al­so fur­ther push the com­pa­ny up the list of top glob­al phar­ma­ceu­ti­cal mak­ers by rev­enue.

Eli Lil­ly keeps putting its GLP-1 wind­fall to use.

On Mon­day, the an­ti-obe­si­ty drug­mak­er an­nounced its lat­est deal to ex­pand its pipeline of fu­ture drugs, say­ing it would spend as much as $2.3 bil­lion on Ajax Ther­a­peu­tics and its clin­i­cal-stage JAK2 work in blood can­cer. Lil­ly and Ajax did­n't dis­close how much of that is in cash, and how much is in fu­ture re­sults-based in­cen­tive pay­outs.

The first test of that bet is like­ly to come lat­er this year, when Ajax's lead drug, AJ1-11095, will re­port proof-of-con­cept da­ta from a Phase 1 tri­al in the rare blood can­cer known as myelofi­bro­sis.

Ther­mo Fish­er Sci­en­tif­ic sells mi­cro­bi­ol­o­gy busi­ness: As­torg, a Eu­ro­pean pri­vate eq­ui­ty firm, will ac­quire the unit for $1.075 bil­lion. Ther­mo Fish­er’s mi­cro­bi­ol­o­gy busi­ness is part of its spe­cial­ty di­ag­nos­tics seg­ment, and fo­cus­es on an­timi­cro­bial sus­cep­ti­bil­i­ty test­ing and oth­er cul­ture work for both phar­ma and food safe­ty test­ing. Ther­mo Fish­er ex­pects the deal to close in the sec­ond half of this year. The an­nounce­ment was light on de­tails, with CEO Marc Casper say­ing the deal “pro­vides ad­di­tion­al cap­i­tal we can de­ploy to cre­ate share­hold­er val­ue.” The com­pa­ny has dis­closed mul­ti­ple rounds of lay­offs this year, as it phas­es out a lab­o­ra­to­ry prod­ucts fac­to­ry in North Car­oli­na and clos­es a chem­i­cal analy­sis man­u­fac­tur­ing site in Mass­a­chu­setts. — Nicole De­Feud­is

In­tel­lia Ther­a­peu­tics re­port­ed this morn­ing on the Phase 3 suc­cess of a gene edit­ing treat­ment for hered­i­tary an­gioede­ma, a dis­ease that caus­es un­pre­dictable, dis­fig­ur­ing and po­ten­tial­ly dan­ger­ous swelling at­tacks. The biotech aims to have its gene edit­ing ther­a­py — the first of its kind to reach this stage — on the mar­ket next year.

In­tel­lia CEO John Leonard spoke with End­points News ahead of the read­out to talk about the find­ings, and what the mile­stone means for a gene edit­ing in­dus­try that has fall­en out of fa­vor re­cent­ly. The fol­low­ing in­ter­view has been edit­ed sub­stan­tial­ly for length and clar­i­ty.

End­points: Where were you when you got the news?

Leonard: I was in a room at In­tel­lia, and our gen­er­al man­ag­er shared the re&s